Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 28th Preview)
-
Cell therapy shutdown after deaths and durability questions
Artiva Biotherapeutics is ending development of its allogeneic, off-the-shelf NK cell program AlloNK after two patient deaths and concerns about clinical response durability, the company said. The biotech also plans to cut about 94% of its workforce and is exploring strategic alternatives, including a merger, sale, or dissolution.
-
Oncology: targeted radiotherapy approach moves into mice for PD-L1-positive TNBC
A preclinical study reported that PD-L1-targeted lutetium-177 therapy reduced tumor volume and extended survival in a mouse model of triple-negative breast cancer. Researchers tested [177Lu]Lu-atezolizumab in athymic mice bearing MDA-MB-231 tumors and saw dose-dependent tumor shrinkage and improved median survival versus saline controls.
-
Regulatory and pipeline: FDA drafts faster pathway for personalized gene therapies
The FDA published draft guidance describing a quicker approval pathway for certain individualized gene therapies, aiming to streamline development in rare-disease settings. The proposal drew attention from patient advocates who have argued for more predictable review timelines for personalized approaches.
-
Dealmaking and fertility innovation: Ferring to acquire Gameto
Ferring Pharmaceuticals agreed to buy fertility treatment startup Gameto in a deal potentially valued at up to $1.4 billion with payments tied to development, regulatory, and sales milestones. Gameto’s platform centers on “Fertilo,” using stem cell-derived ovarian support cells to grow eggs outside the body, aiming to reduce reliance on hormone injections and shorten IVF cycle timelines.
-
Public markets: biotech IPO activity stays hot despite mixed index moves
Biotech IPOs raised $7.5 billion across 22 offerings in the first three quarters of 2026, reflecting a revived public-market window even as the biotech index’s recent quarter performance flattened, according to a J.P. Morgan-referenced roundup. The report also highlighted momentum from reverse mergers and the continued concentration of capital in established life-sciences ecosystems.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.